



[Science](#)[Education](#)[Patient Care](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2025](#)[Organisational Structure 2025](#)[Financial Highlights 2025](#)[EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print




Per Ljungman
Registry Committee Chair
Sweden



Antonio Risitano
SCIENTIFIC COUNCIL representative with the Registry portfolio, Registry Committee
Co-Chair, SAAWP Chair
Italy

In 2025, **37.329 new patients** were registered in the EBMT Registry. 18.875 new allogeneic HCTs were reported, 18.504 autologous HCTs, and 4.757 CAR-Ts. These trends are consistent with previous years.



In total, the EBMT Registry had **804.745 patients** on December 31, 2025. Patients can be classified into 13 diagnosis classifications.

Diagnosis classification	Count of diagnosis events
Acute leukaemia	218.155
Autoimmune disease	5.155
Bone Marrow Failure incl. Aplastic Aneamia	25.550
Chronic leukaemia	34.296
Hemoglobinopathy	10.562
Inborn Errors	13.520
Lymphoma	220.622
Myelodysplastic syndrome	30.438
Myelodysplastic/myeloproliferative disease	7.422

Diagnosis classification	Count of diagnosis events
Myeloproliferative disorder	12.904
Other Diagnosis	2.669
Plasma cell neoplasm	212.450
Solid tumour	51.864
Total diagnosis events	845.607

EBMT Registry

In October 2025, EBMT achieved **ISO/IEC 27001:2022 certification**, demonstrating the EBMT Registry adheres to the international standards for safely storing and processing data.

The EBMT Registry itself had **seven releases** that introduced **new functionality**. With the addition of summary fields on patients, an audit trail, and export functionality, it has been made easier for users to quickly access any data they need. Several technical updates were made for improved system and study management. **MicroStrategy**, the exporting tool launched in 2024, has been migrated to an optimised cloud environment with improved performance and additional functionality. On top of that, ten new reports were added to the library.

A new EBMT megafile has been developed to enable effective reporting from the registry, focusing on working-party-initiated studies.

2025 also marked the year the **EuroTraCTOR** grant closed, which started in 2022 and has been a cornerstone of the EBMT Registry's development through collaboration with the consortium partners.

Studies

In the first half of the year, the EBMT Registry **Study Manager** was being piloted with two studies from Working Parties. After a successful evaluation, additional functionalities were added, and more studies are being rolled out. The Study Manager tool will allow Working Parties to manage all study-related information, including additional data collection, inside one platform to improve efficiency on studies.

Communication

Every eight weeks, representatives from the Registry Unit met with the national registries to inform them about ongoing developments and projects. In these meetings the national registry stakeholders also provided the Registry Unit with valuable feedback on the EBMT Registry and projects. The Registry Committee held monthly meetings to discuss ongoing issues and difficulties reported from various stakeholders. Next to this, all EBMT Registry users received monthly newsletters with updates.

Team

The [Registry Unit](#) acquired one new IT analyst in 2025, who works from the Barcelona office. The Registry Unit now consists of one manager, one IT team lead, one data operations team lead, one data management specialist, four IT analysts, three data managers, and one data steward. The team is located in Spain and the Netherlands.

Future

In 2026, the Registry Unit's goals are centred around stability and consolidation of good practices, implementing strong data governance policies together with data quality procedures to ensure the data provided by EBMT's members can be used to support EBMT's mission of saving and improving the lives of patients with blood-related disorders. Updated data collection forms are being developed with a planned launch in April 2026, after the Annual Meeting. The aim is to focus on the important variables of the core dataset and moving several variables to the extended dataset. This will allow focussing on EBMT studies and reducing the workload of the centres reporting data.